Ethic Inc’s Akebia Therapeutics AKBA Stock Holding History

Ethic Inc’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42,260	Closed	-$115K	–	1212
2025 Q3	$115K	Buy	42,260 +1,722	+4%	+$5.73K	﹤0.01%	1144
2025 Q2	$148K	Buy	40,538 +28,748	+244%	+$79K	﹤0.01%	1144
2025 Q1	$22.5K	Buy	+11,790	New	+$24.1K	﹤0.01%	1153

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ethic Inc's AKBA Position: Q4 2025 in Review

Ethic Inc sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 42,260 shares — an estimated $115K sold.

Ethic Inc first reported a position in AKBA in Q1 2025 and held it in 3 quarters. The position peaked at $148K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Ethic Inc reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Ethic Inc sold 42,260 Akebia Therapeutics shares in Q4 2025, an estimated $115K.
Ethic Inc first reported a position in Akebia Therapeutics in Q1 2025 and held it in 3 quarters.
Ethic Inc's Akebia Therapeutics position peaked at $148K in Q2 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Ethic Inc's 13F filing for Q4 2025, filed 3 Feb 2026.